Synthetic Multivalent Antibodies for Persistent Pseudomonas Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutics for treating multidrug-resistant Pseudomonas spp. infections and biofilm formation on medical devices are costly and require frequent administration, posing challenges in managing chronic conditions.
Innovation Solution
A recombinant nucleic acid sequence encoding synthetic antibodies, such as pentameric IgM antibodies, is administered to generate antibodies in vivo that bind to Pseudomonas antigens, providing rapid and effective immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If purified antibodies are manufactured and administered for treating Pseudomonas infections, then therapeutic efficacy is improved, but treatment cost increases significantly
Solution Approach 1:
The patent enables the patient's own body to produce the therapeutic antibodies through in vivo expression of nucleic acid sequences encoding the antibodies. This self-service approach eliminates the need for external manufacturing, purification, and administration of costly purified antibodies, thereby significantly reducing treatment costs while maintaining therapeutic efficacy.
Solution Approach 2:
The patent introduces nucleic acid sequences encoding therapeutic antibodies into the patient's system in advance, allowing the body to continuously produce the antibodies before and during infection. This preliminary action ensures immediate therapeutic availability without waiting for external antibody administration, reducing both cost and treatment delay.
2Duration of action of stationary object
If purified antibodies are administered weekly to monthly for chronic conditions, then therapeutic coverage is maintained, but treatment complexity and burden increase
Solution Approach 1:
By enabling the patient's body to autonomously produce therapeutic antibodies through in vivo expression of encoded sequences, the patent eliminates the need for repeated external administrations. The body continuously manufactures the antibodies, maintaining therapeutic coverage without requiring weekly to monthly clinic visits or self-administration, thereby greatly simplifying treatment operations.
Solution Approach 2:
The patent establishes continuous antibody production within the patient's body through sustained expression of the introduced nucleic acid sequences. This continuous in vivo synthesis ensures uninterrupted therapeutic coverage, replacing the discontinuous external administration schedule and eliminating gaps between doses.
3Object-affected harmful factors
If high levels of antibiotics are used to treat biofilm-forming Pseudomonas, then bacterial growth is suppressed, but antibiotic resistance increases
Solution Approach 1:
The patent converts the harmful effect of antibiotic resistance into a beneficial alternative therapy by using therapeutic antibodies that target specific Pseudomonas antigens. Instead of relying on antibiotics to which bacteria have developed resistance, the antibodies provide a different mechanism of action that bypasses antibiotic resistance pathways, effectively treating infections without selecting for further resistance.
Solution Approach 2:
The patent extracts the therapeutic function from antibiotics and transfers it to antibody-based therapy. By isolating the specific antigen-antibody interaction mechanism and applying it to Pseudomonas targets, the patent creates a treatment modality that is independent of antibiotic resistance mechanisms, effectively removing the resistance problem from the treatment equation.
Data Source
AI summary
Disclosed herein are compositions for generating a synthetic antibody or synthetic multivalent antibody in a subject. Also disclosed are methods for generating a synthetic antibody or synthetic multivalent antibody in a subject by administering a composition including a recombinant nucleic acid sequence that encodes an antibody, a synthetic antibody, or a synthetic multivalent antibody to a subject. The disclosure also provides compositions and methods of preventing and/or treating a bacterial infection in a subject using said antibody, synthetic antibody, or synthetic multivalent antibody.